GP IIb/IIIa inhibition in primary stenting: 'do it early, make it easy'

被引：4

作者：

Montalescot, G ^{[1
]}

机构：

[1] Ctr Hosp Univ Pitie Salpetriere, Serv Cardiol, Paris, France

来源：

EUROPEAN HEART JOURNAL | 2002年 / 23卷 / 04期

关键词：

D O I：

10.1053/euhj.2001.2948

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：259 / 260

页数：2

共 4 条

[1] Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention [J].

Anderson, KM ;

Califf, RM ;

Stone, GW ;

Neumann, FJ ;

Montalescot, G ;

Miller, DP ;

Ferguson, JJ ;

Willerson, JT ;

Weisman, HF ;

Topol, EJ .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (08) :2059-2065

[2]

Collet JP, 2001, CIRCULATION, V103, P2328

[3] Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. [J].

Montalescot, G ;

Barragan, P ;

Wittenberg, O ;

Ecollan, P ;

Elhadad, S ;

Villain, P ;

Boulenc, JM ;

Morice, MC ;

Maillard, L ;

Pansiéri, M ;

Choussat, R ;

Pinton, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) :1895-1903

[4] Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial [J].

Topol, EJ ;

Mark, DB ;

Lincoff, AM ;

Cohen, E ;

Burton, J ;

Kleiman, N ;

Talley, D ;

Sapp, S ;

Booth, J ;

Cabot, CF ;

Anderson, KM ;

Califf, RM .

LANCET, 1999, 354 (9195) :2019-2024

← 1 →